Shares of Nanthealth LLC (NYSE:NH) hit a new 52-week low during trading on Friday . The company traded as low as $12.36 and last traded at $12.56, with a volume of 54,235 shares trading hands. The stock had previously closed at $12.64.

A number of analysts have commented on NH shares. Cowen and Company started coverage on shares of Nanthealth in a research note on Monday, June 27th. They issued an “outperform” rating and a $19.00 price target for the company. Jefferies Group started coverage on shares of Nanthealth in a research note on Monday, June 27th. They issued a “buy” rating for the company. Canaccord Genuity started coverage on shares of Nanthealth in a research note on Monday, June 27th. They issued a “buy” rating and a $17.00 price target for the company. FBR & Co started coverage on shares of Nanthealth in a research note on Monday, June 27th. They issued an “outperform” rating and a $18.00 price target for the company. Finally, First Analysis started coverage on shares of Nanthealth in a research note on Monday, June 27th. They issued an “overweight” rating and a $18.00 price target for the company. Five equities research analysts have rated the stock with a buy rating, The company currently has an average rating of “Buy” and a consensus price target of $18.00.

The stock has a 50 day moving average price of $13.67 and a 200-day moving average price of $13.67. The company’s market capitalization is $6.94 billion.

In other Nanthealth news, CEO Patrick Soon-Shiong purchased 357,143 shares of the firm’s stock in a transaction on Tuesday, June 7th. The stock was acquired at an average price of $14.00 per share, for a total transaction of $5,000,002.00. The purchase was disclosed in a legal filing with the SEC, which is available at this link. Also, major shareholder Healthcare Solution Allscripts purchased 714,286 shares of the firm’s stock in a transaction on Tuesday, June 7th. The shares were acquired at an average price of $14.00 per share, with a total value of $10,000,004.00. Following the purchase, the insider now directly owns 15,000,000 shares in the company, valued at approximately $210,000,000. The disclosure for this purchase can be found here.

Nant Health, LLC is an evidence-based, personalized healthcare company. The Company’s systems-based approach to personalized healthcare applies diagnostics tailored to the specific molecular profiles of patient tissues and integrates this molecular data in a clinical setting with real-time biometric signal and phenotypic data to track patient outcomes and deliver medicine.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.